DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. MU
2. QCOM
3. SPY
4. ICLR
5. JPM
6. USO
7. FUL
8. LAES

Go back to DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
(NASDAQ: DMAC) Delayed: 6.15 -0.21 (3.3%)
Previous Close $6.36    52 Week High $ 
Open $6.47    52 Week Low $ 
Day High $6.57    P/E N/A 
Day Low $6.13    EPS $ 
Volume 109,096